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Abstract
The growing incidence of type 2 diabetes (T2D) is a significant health concern, rep-
resenting 90% of diabetes cases worldwide. As the disease progresses, resultant insu-
lin deficiency and hyperglycaemia necessitates insulin therapy in many cases. It has
been recognized that a significant number of people who have a clinical requirement
for insulin therapy, as well as their healthcare professionals, are reluctant to intensify
treatment with insulin due to fear of hypoglycaemia, poor understanding of treat-
ment regimens or lack of engagement, and are therefore at higher risk of developing
complications from poor glycaemic control. Over the past decade, the rise of diabetes
technologies, including dosing advisors, continuous glucose monitoring systems, insu-
lin pumps and automated insulin delivery systems, has led to great improvements in
the therapies available, particularly to those requiring insulin. Although the focus has
largely been on delivering these therapies to the type 1 diabetes population, it is
becoming increasingly recognized that people with T2D face similar challenges to
achieve recommended glycaemic standards and also have the potential to benefit
from these advances. In this review, we discuss diabetes technologies that are cur-
rently available for people with T2D and the evidence supporting their use, as well as
future prospects. We conclude that there is a clinical need to extend the use of these
technologies to the T2D population to curb the consequences of suboptimal disease
management in this group.
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1 | INTRODUCTION
Diabetes is a major global health problem, affecting an estimated
463 million adults and a rising number of younger individuals world-
wide. Approximately 90% of all cases of diabetes are type 2 (T2D) and
the overall number is rapidly increasing,1 causing significant burden
for those affected and growing strain on healthcare resources.
Despite the widening choice of oral and injectable antihyperglycaemic
agents to treat T2D and the availability of long- and fast-acting insulin
analogues, many people struggle to achieve recommended glycaemic
targets and are at risk of developing long-term micro- and
macrovascular complications.2
Although there is clear recognition of the need to intensify
treatment for many people with T2D, timely and appropriate
intensification of insulin therapy does not occur,3 possibly due to
fear of side effects, individual choice or low health literacy.
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Recent advances in technology provide valuable means of
improving the accuracy and safety of insulin therapy and simplify-
ing glucose monitoring.4 This should be harnessed to encourage
appropriate intensification of treatment with the goal of improv-
ing outcomes.
To date, much research in diabetes technology has been directed
towards treatment of type 1 diabetes (T1D)5 where a near absence of
β-cell function necessitates lifelong insulin therapy. Hybrid closed-
loop systems are now commercially available for people with T1D,6
but evidence for their use in people with T2D lags behind. Although
the pathophysiology of T2D differs, it is appropriate that the ability of
technology to improve glycaemic control in T1D is extended to people
with T2D.
This review discusses clinical evidence and diabetes technologies
that have been applied in the treatment of T2D over the past decade.
We explore technologies that are currently in use, possibilities for the
future, and relevant guidelines from professional bodies on how these
technologies can be utilised.
We reviewed the relevant literature available from PubMed on
diabetes technology in people with T2D from January 2010 until
November 2020 using the search terms: “closed-loop”; “hybrid
closed-loop”; “artificial pancreas”; “self-monitoring blood glucose”;
“continuous glucose monitor”; “flash glucose monitoring”; “type 2 dia-
betes”; “insulin pump therapy”; “continuous subcutaneous insulin
infusion”; “diabetes technology”; “digital technology”; “mobile
phone”; and “smart insulin pen.” Studies involving pregnant women
are excluded, as are studies investigating non-technology pharmaco-
logical approaches.
2 | CONTEMPORARY DIABETES
TECHNOLOGIES
Figure 1 displays contemporary diabetes technologies available for
use by people with T2D, and the associated clinical benefits.
Traditionally, T2D has been managed in a stepwise approach,
beginning with lifestyle interventions and progressing to one or more
oral antihyperglycaemic agents, and ultimately many people require
insulin therapy as the disease progresses further.7,8 An estimation of
global insulin requirements for T2D between 2018 and 2030 suggests
that, if insulin becomes widely available and is used appropriately to
achieve glycated haemoglobin (HbA1c) levels of less than 53mmol/
mol, approximately 15.5% of people with T2D worldwide will require
insulin therapy.9
In the past decade, many advances in diabetes technology have
focused on safer and more accurate glucose measurement and insulin
delivery, therefore, it should be acknowledged that these technologies
will be of particular advantage to those on insulin therapy. The spec-
trum of new technologies spans from motivational smartphone appli-
cations (apps) which can benefit noninsulin-requiring users, to
modification of insulin pens, and simplified insulin pumps that inte-
grate with continuous glucose monitors to function as an “artificial
pancreas” for those on insulin therapy. For older adults with high
comorbidity burden, these technologies may be less appropriate. A
key focus should be the adoption of a user-centred approach, consid-
ering individual preference, technical ability and treatment goals to
allow appropriate integration of incoming technologies into
standard care.
F IGURE 1 Venn diagram illustrating
contemporary diabetes technologies and
associated clinical benefits based on a
review of the available literature
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3 | TECHNOLOGY-ENABLED SELF-
MANAGEMENT
For some people with early T2D, evidence has shown reversibility of
the disease with lifestyle modification.10 For this reason, particular
attention is given to promotion of exercise, healthy diet and education
for minimizing cardiovascular risk.8
Coinciding with an increase in smartphone use over the past
decade, a number of smartphone apps have been designed to
empower users with T2D to engage with lifestyle modification and
promote diabetes self-management. The literature has been con-
flicting, with a number of small studies and randomized controlled tri-
als (RCTs) reporting improvements in HbA1c, cardiovascular benefits
and positive feedback from users and healthcare professionals follow-
ing use of a smartphone app,11–16 while other studies have been less
encouraging, with an RCT by Agarwal et al17 (n = 223) showing no
HbA1c reduction and no improvement in quality of life or diabetes
self-efficacy following use of a US Food and Drug Administration-
approved app “BlueStar,” possibly linked to a low app usage. A quali-
tative study by Torbjørnsen et al18 also suggested low acceptability of
apps and higher clinical and digital distress during periods of use.
In line with the findings of a meta-analysis of 14 studies by Hou
et al,19 it can be concluded that smartphone apps may be considered
as an adjunct to improve HbA1c in people with T2D but acceptability
and functionality must align with the digital literacy of the target pop-
ulation. For those unfamiliar with smartphone technology, a more
practical approach may involve increased education and greater
involvement of primary care to promote cardiovascular health.20
4 | GLUCOSE MONITORING
In contrast to the T1D population with a minimum recommended
blood glucose measurement frequency of four times daily,21 the
requirement for glucose monitoring in people with T2D is less clear.8
The National Institute for Health and Care Excellence (NICE) does not
recommend self-monitoring of blood glucose (SMBG) for people with
noninsulin-treated T2D unless during pregnancy or in people at risk of
hypoglycaemia, due to minimal clinical benefit, increased burden and
cost.22,23 An RCT involving 450 people with noninsulin-treated T2D
showed no improvement in HbA1c or quality of life in those who used
SMBG compared to those who did not.24
4.1 | Self-monitoring of blood glucose
In people with insulin-treated T2D, the literature is conflicting on the
benefits of SMBG. An RCT by Nauck et al25 showed no improvement
in glycaemic control with weekly SMBG profiling compared to no
SMBG in people with T2D on conventional insulin therapy (basal insu-
lin once daily or premixed insulin twice daily). Treatment intensifica-
tion was more likely in the monitoring group, suggesting earlier
identification of the need for therapy adjustments. A meta-analysis
involving 5454 people with T2D in 24 studies concluded that
glycaemic control was superior in SMBG groups compared to control
groups at 12 and 24 weeks, with greater improvements seen in those
with higher baseline HbA1c.26 At 1 year, however, this did not reach
significance, suggesting no sustained benefits of SMBG on glycaemic
control. Of note, only four of the 24 studies included people on insulin
therapy.26
Burden and costs associated with SMBG may reduce user
engagement. Furthermore, “point-in-time” glucose measurements and
the absence of information on glucose trends or variability limit the
clinical utility of SMBG and fail to detect nocturnal or asymptomatic
hypoglycaemia. With the ability to overcome these limitations, flash
glucose monitoring and continuous glucose monitoring (CGM) have
gained popularity. These devices provide instantaneous information
on glucose trends and variability, warnings for out-of-range glucose
values as well as the ability to remotely review glucose profiles, all-
owing healthcare professionals and users to make required
adjustments.27
4.2 | Flash glucose monitoring
A novel approach to glucose monitoring available since 2016 involves
the use of a factory-calibrated 14-day flash glucose monitor, the Free-
Style Libre28 (Abbott Diabetes Care, Alameda, California). A small cir-
cular sensor containing a thin fibre is inserted in the upper arm and
records interstitial glucose every minute. Eight hours' worth of glu-
cose values are stored by the device, therefore, a minimum of three
scans per day at 8-hour intervals enables recording of a full day of glu-
cose values. Use of a handheld reader or a “near-field communica-
tion”-enabled smartphone to scan the sensor results in production of
an ambulatory glucose profile (AGP), providing a minimally invasive
and rapid method of glucose monitoring and the ability to assess glu-
cose trends and variability throughout the day and night.29 Studies
have shown high user satisfaction due to fewer finger pricks, ease of
use and ease of insertion of the device.30–33
A number of RCTs and a meta-analysis by Castellana et al
(2020) showed improvements in HbA1c and reduced time in
hypoglycaemia with the use of flash glucose monitoring compared
to SMBG in insulin-treated T2D.33–35 By contrast, a multicentre
RCT by Haak et al36 (n = 224) and an RCT by Furler et al37
(n = 299) showed no difference in HbA1c but greater time in range
and less time in hypoglycaemia, suggesting particular benefit for
people prone to hypoglycaemia. It should be noted, however, that
secondary endpoint analysis of the RCT by Haak et al36 showed
significant HbA1c reduction in participants aged <65 years,
suggesting an inverse relationship of HbA1c with age. Possible rea-
sons for this include lower engagement with sensor scanning, less
interaction with AGPs or a reluctance to alter insulin doses among
the older age groups. The absence of HbA1c reduction following
the use of masked professional-mode flash glucose monitoring seen
in the RCT by Furler et al37 suggests that direct user interaction
and adjustments to therapy may be the driving force behind HbA1c
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reduction. Despite this, people with T2D using the masked “Libre
Pro” reported increased understanding of therapies and improved
self-management of their diabetes due to interaction with AGPs
alongside their clinical team.35
Measurement accuracy of a glucose sensor underpins its clinical utility
and safety. Accuracy is commonly assessed using mean absolute relative
difference (MARD), with lower values indicating increased accuracy
against reference glucose values.38 A MARD of ≤10% has been hypothe-
sized to facilitate nonadjunctive use of glucose sensors, while improve-
ments to achieve a MARD of <10% have not been shown to improve
glycaemic outcomes.39 The FreeStyle Libre has been shown to be consis-
tent and accurate over a 14-day period of usewith aMARDof 11.4%.30,40
Costwise, flash glucose monitoring is comparable to SMBG 8.3
times daily in the UK, which is above the average testing frequency
seen in people with T2D.36 From a health service perspective,
increased use of resources with SMBG compared to flash glucose
monitoring based on observations from the REPLACE trial estimate
total annual costs of flash glucose monitoring in the UK to be 13%
lower than SMBG in people with T2D.41 Thus, reductions in complica-
tions, reduced fingerstick testing and fewer hospital admissions may
deem this a cost-effective option.
Limitations of the first-generation flash glucose monitoring sys-
tem include the lack of alerts for hypo- or hyperglycaemia which has
been addressed in the newer FreeStyle Libre 2, which displays an alert
for out-of-range glucose values along with a prompt to check glucose.
A smaller and thinner FreeStyle Libre 3 with full CGM capabilities is
planned to become available in the European Union at the same price
as previous versions.42
4.3 | Professional guidelines on the use of flash
glucose monitoring
A Medtech innovation briefing by NICE in 2017 on the use of the
FreeStyle Libre stated the device could be used to replace routine
blood glucose monitoring in people with T2D on insulin therapy,
but highlighted that people on fixed doses of insulin may derive less
benefit. Reflecting results from clinical trials, it was also noted that
the FreeStyle Libre may be particularly beneficial to people with
T2D experiencing frequent hypoglycaemia.43 Despite this, the use
of the FreeStyle Libre is yet to be incorporated into NICE guide-
lines for the management of T2D in adults. The American Diabetes
Association (ADA) has updated guidelines on the use of the device,
stating that for insulin-treated people with T2D who are not
meeting glycaemic targets, intermittently scanned continuous glu-
cose monitors can be used to lower HbA1c and/or reduce
hypoglycaemia.44
4.4 | Continuous glucose monitoring
The limitations of flash glucose monitoring can be overcome by the
use of CGM devices, which provide regular, real-time data and alerts/
alarms without the need to physically scan a sensor. Improved design
and accuracy has accelerated their use, particularly among people
with T1D, with more evidence emerging for their use in T2D.
Historically, HbA1c measurements and SMBG have been the pri-
mary methods to assess glycaemia in people with insulin-treated T2D,
however, there are limitations to these measures. HbA1c has been
shown to be unreliable in certain groups45 and provides no information
on glucose patterns, undetected hypoglycaemia or glucose variability.
As a result, percentage of time in range captured by CGM systems is
expected to supersede HbA1c as the preferred metric for assessing
glycaemic control and risk of complications in T1D and T2D.27,46
In contrast to the results of a number of RCTs showing no
improvement in HbA1c with the use of flash glucose monitoring in
T2D,36 an RCT by Beck et al47 involving 158 adults with insulin-
treated T2D using CGM technology over 24 weeks showed increased
time in range and a reduction in HbA1c of at least 0.5% in 73% of the
CGM group, compared to 49% of a control group (adjusted difference
in mean change in HbA1c from baseline 0.3% [confidence interval
0.5% to 0.0%]; P = 0.022). This was consistent across all age groups,
ranging from 35 to 79 years. Analysis of hypoglycaemia-related end-
points was limited by the low percentage of time in biochemical
hypoglycaemia and the absence of severe hypoglycaemia in both
groups. Further studies with follow-up periods extending beyond
24 weeks would be beneficial in this regard, and to ensure HbA1c
reductions are sustained. Although quality-of-life measures did not
differ significantly between CGM and control groups in this RCT, high
user satisfaction was reported with CGM and more than 90% of users
averaged 6 or more days of CGM use per week.47
A key benefit of CGM use in insulin-treated T2D is the ability to
program alerts for hypoglycaemia. This is reflected in the International
Consensus guidelines for the use of CGM devices, which advise that
this technology “should be considered, along with HbA1c, to assess
glycaemia in patients with insulin-treated T2D, especially if experienc-
ing problematic hypoglycaemia”.27,44 Identification of asymptomatic
and nocturnal hypoglycaemia on AGPs allows for earlier recognition
of the need to dose-adjust, and importantly, improves confidence that
insulin therapy can be safely intensified.
Until recently, a deterrent to the adoption of CGMs in clinical
practice was the need for calibration with fingerstick glucose to com-
bat changes in sensor sensitivity over time. The release of a CGM with
no requirement for calibration, the Dexcom G648,49 (Dexcom, San
Diego, California), has enhanced quality of life for many users by elimi-
nating this need to perform regular fingerstick testing.
Aside from the glycaemic benefits of CGM, it has been postulated
that the ability to review continuous glucose data promotes healthy life-
style practices and motivation to exercise,50,51 reducing insulin resistance
and improving cardiovascular health in this high-risk group.52
4.5 | Implantable glucose monitors
The first implantable CGM (Eversense; Senseonics Inc., Germantown,
Maryland) has been available since 2016 and consists of a small
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cylindrical-shaped sensor inserted in the upper arm by a trained profes-
sional. Along with a wearable transmitter placed over the sensor and a
smartphone app, this provides glucose data for up to 180 days.53 Three
pivotal studies including patients with T2D were carried out to evaluate
the safety and accuracy of Eversense CGM and concluded that the sys-
tem displayed accurate readings throughout the entirety of sensor life
and had a favourable safety profile compared with traditional transcuta-
neous CGM devices.54–56 The longer duration and implantable nature of
the sensor make this a preferable option for patients who dislike or have
difficulty with frequent sensor changes, patients who may benefit from
“on-body” alerts via the vibrating mechanism of the transmitter, or
patients with allergies to standard CGM adhesives.53 On the other hand,
the inconvenience of a minor surgical procedure for insertion and
removal of the device and the requirement to book a visit with a
healthcare professional in the case of sensor failure is likely to deter
some users.57 Currently, the 90-day implantable Eversense® CGM sys-
tem (Senseonics) has been approved for non-adjunctive use in the
United States, and the 180-day Eversense XL® system has been
approved for adjunctive use in Europe.
Similar to flash glucose monitoring, ADA recommendations
state that CGM devices can be used to help lower HbA1c and/or
reduce hypoglycaemia in adults with T2D who are not meeting
glycaemic targets. In addition, the use of masked CGMs to charac-
terize glycaemic patterns, enabling earlier adjustments to therapy,
has also been highlighted as beneficial for people with T2D.44 NICE
guidelines for T2D do not currently include any recommendation
for CGM use, however, a NICE surveillance report in June 2019
flagged this as an area for review.58 Table 1 shows currently avail-
able CGM systems for people with T2D.
5 | INSULIN DELIVERY
5.1 | Insulin pens
Insulin pens are the most widely used method of insulin administration in
people with T2D.59 The basic insulin pen delivers subcutaneous insulin
from a cartridge via a disposable needle. Although this is a convenient
approach for insulin administration, the requirement for manual record
keeping of blood glucose readings, and the lack of connection to a digital
ecosystem make it challenging for healthcare professionals and users to
interpret glucose profiles or assess dosing adherence.
Advances in insulin pen design over the last decade have resulted
in the addition of memory function, caps, attachments, and ultimately
“smart insulin pens” with the ability to track doses and upload data to
online platforms. “Memory” function, whereby the insulin pen stores
and displays information on previous bolus timing and amount, is par-
ticularly useful for people with cognitive impairment, or those with a
lack of engagement in diabetes management due to the complexity of
dosing regimens.60
Bluetooth-enabled insulin pen caps and attachments that link to
smartphone apps allow users to track boluses, calculate remaining
insulin, monitor insulin temperature and receive dosing reminders.61
Perhaps most useful is the ability of smart insulin pens to combine
the above features with CGM data and upload to online platforms to
enable healthcare professionals to remotely review and make adjust-
ments to therapy.62,63 It has been shown that people with lower
adherence to insulin dosing have poorer glycaemic control,64 there-
fore, smart pens may provide an effective method of highlighting
those requiring education and support with behaviour modification at
an earlier stage. Studies in the T1D population have shown increased
dosing adherence and glycaemic improvements with smart pen
use.65To our knowledge, no studies have been published on glycaemic
outcomes, impact on quality of life or cost-effectiveness of smart pen
use in people with T2D. The ongoing clinical trial (NCT04678661)
aims to investigate effects on glycaemic control, feasibility and usabil-
ity of a smart pen consisting of a clip-on dose recorder with wireless
connection to a “My Dose Coach smartphone app” that provides dos-
ing suggestions for people with T2D on once-daily basal insulin.
Table 2 presents currently available smart pens and associated fea-
tures for use by people with T2D.
5.2 | Insulin pumps
Insulin pump therapy, or continuous subcutaneous insulin infusion
(CSII), has been in use since the 1970s and aims to mimic physiological
insulin delivery for people with diabetes. Rapid-acting insulin is admin-
istered from a refillable reservoir into subcutaneous tissue at pre-
programmed rates via a steel or plastic cannula, which is replaced
TABLE 1 Currently available continuous glucose monitoring systems for use in people with type 2 diabetes
CGM system Manufacturer Sensor duration, days Territories
Dexcom G6 Dexcom, San Diego, California 10 United States and Europe
FreeStyle Libre 1 Abbott Diabetes Care, Alameda, California 14 United States and Europe
FreeStyle Libre 2 Abbott Diabetes Care, Alameda, California 14 United States and Europe
GlucoMen Day Menarini Diagnostics, Florence, Italy 14 Europe
Eversense Senseonics, Germantown, Maryland 90 United States
Eversense XL Senseonics, Germantown, Maryland 180 Europe
S7 EasySense Medtrum, Shanghai, China 14 Europe
Guardian Connect Medtronic Diabetes, Northridge, California 6 United States and Europe
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every 48 to 72 hours. Insulin pumps have become more user-friendly,
compact and reliable, resulting in increased popularity among people
with diabetes, particularly in the paediatric T1D population.70
Current NICE guidelines advise against the use of CSII for people
with T2D,71 and a consensus statement from the ADA and the
European Association for the Study of Diabetes (EASD) in 2018 only
briefly referred to a limited role for insulin pumps in a minority of peo-
ple with T2D.23 In recent years, evidence has been building that CSII
in T2D is more effective and safer than conventional insulin therapy
and indeed, the most recently updated ADA Standards of Medical
Care in Diabetes (2021) recommend that insulin pumps can be consid-
ered as a treatment option for adults and youth with T2D who are on
multiple daily injections (MDI) and able to manage the device.72
Over the past decade, several small uncontrolled studies have
shown improvements in glycaemic control, reductions in insulin
requirements and improved quality of life for adults with T2D on
CSII versus MDI or oral agents.73–75 These findings were corrobo-
rated by a retrospective observational study by Reznik et al71
involving 102 adults with T2D newly commenced on insulin pump
therapy. Of the participants, 93% were previously treated with
insulin. HbA1c at 1 year improved from 9.3 ± 1.8% to 7.4 ± 1.4%,
which was maintained at 6 years, suggesting long-lasting benefits
of CSII use. Most notably, HbA1c reductions were noted in those
with a baseline HbA1c level above 8% and in those previously on
oral diabetes drugs compared to basal-bolus therapy before initia-
tion on insulin pump therapy.75
Larger RCTs including VIVID (n = 365),76 OpT2mise (n = 331)77
and a meta-analysis by Pickup et al66 corroborated these findings of
superior glucose control, lower total daily dose and high treatment
satisfaction with CSII compared to MDI in adults with T2D.78 Impor-
tantly, there was no increase in the incidence of hypoglycaemia.79
Pickup et al66 highlight an important concept in the above-
mentioned studies, that the greatest HbA1c improvement was seen in
the OpT2mise study which is unique in its inclusion of a 2-month run-
in period prior to randomization to optimize glycaemic control on
basal-bolus therapy. This implies that the cohort of people who strug-
gle to achieve optimal glycaemic control after careful dose titration,
dietary and physical interventions are most likely to benefit from CSII
therapy.
Smaller studies comparing CSII to MDI use in T2D suggested a
greater degree of weight gain with the former,75,80,81 which is an
important consideration given the higher cardiovascular risk in this
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group compared to those without diabetes. The results of the larger
VIVID76 and OpT2mise77 RCTs, and meta-analysis by Pickup et al66
were reassuring, as no significant difference in weight gain was
observed. As weight gain is a commonly reported reason for avoid-
ance of insulin therapy in T2D, this is an important point to reiterate
to clinicians and people who have expressed these concerns.82
Although many people with T2D have difficulty achieving glucose
targets and therefore meet criteria for insulin therapy, a major barrier
to treatment intensification is the fear of hypoglycaemia. It is known
that severe hypoglycaemia in people with T2D is associated with
microvascular and macrovascular adverse events and death.83,84 This
has resulted in healthcare professionals inappropriately adopting
“safer” and often insufficient insulin intensification, which is defined
as “clinical inertia”. Although this applies to all methods of insulin
delivery, it could be argued that greater knowledge of MDI therapy
and more flexibility to prescribe “safer” doses to avoid hypoglycaemia
may lead to preference for MDI over pump therapy. Limited expertise
of healthcare providers in the use of insulin pumps in general may rep-
resent a barrier to widespread adoption of pump use.
As with all technology, it is important to consider usability to
ensure the target population will derive the intended benefits. An
RCT by Chamberlain et al85 assessed user perceptions and usability of
two insulin pumps using a usability scale in 28 participants including
12 adults with T2D previously on MDI. The study concluded that user
perceptions of usability significantly influence attitudes towards com-
mencing insulin pump therapy, even in younger age groups.85 Simi-
larly, Reznik et al75 showed that participants who were completely
autonomous using their insulin pump, or participants who involved a
nurse to manage their pump had greater HbA1c improvements com-
pared to those who were only technically autonomous. This highlights
a need for simpler designs and user-friendly devices to encourage
uptake across all ages. In older age groups, other barriers to uptake
may include cognitive decline, eyesight problems or lack of manual
dexterity.86 For this reason, insulin pump manufacturers have focused
on improving designs to reduce training needs and potential for user
error.87
Despite concerns regarding the ability of older individuals to man-
age an insulin pump, it is encouraging that although 38% of partici-
pants in the insulin pump therapy group of the OpT2mise trial had
cognitive impairment, this did not impact on insulin pump efficacy or
safety for these users.88 Other studies have been carried out in peo-
ple with T2D to investigate the use of simplified and more affordable
insulin pumps with no requirement for pump programming or detailed
education sessions, for example, the “V-Go” 24-hour disposable patch
pump89 and “PAQ” wearable 3-day CSII device with predefined basal
insulin and on-demand boluses.90 Significant improvements in HbA1c
were noted and patients reported a preference for the simplified CSII
device over insulin injections. These findings suggest that adjunctive
technologies including bolus calculator, temporary basal rates and car-
bohydrate ratio determination with meals are not necessary to
improve glycaemic control in this group,91 and that insulin pump ther-
apy can be further simplified in T2D, with the goal of encouraging
more people to avail themselves of it.
Although, typically, T2D has been associated with older age
groups compared to T1D, it is worth noting that the incidence of T2D
is increasing across all age groups. The ADA has now recommended
screening for T2D in children from age 10 or at onset of puberty in
children who are obese with risk factors.92 It is foreseeable that the
growing cohort of younger persons with T2D will be adaptable to
the use of technology, and more likely to reap the benefits of tighter
glucose control over a longer time period.
Despite higher initial acquisition costs of insulin pump therapy
compared to MDI, there have been numerous studies demonstrating
the long-term cost-effectiveness of CSII therapy in T2D. This is mainly
driven by reductions in diabetes-related complications and lower daily
insulin requirements on CSII compared to MDI.93,94 A simulation
study of the OpT2mise study estimated an 8.3% overall relative risk
reduction for any cardiovascular event, and lifetime-discounted sav-
ings of US$ 66,883 over 40 years with the use of CSII compared to
MDI.95 Optimization of insulin therapy using CSII has also been
shown to reduce the need for concomitant oral antihyperglycaemic
agents, reducing costs and polypharmacy.96 For people with T2D and
for healthcare systems, fewer hospital admissions, emergency depart-
ment attendances and clinic appointments provide a strong argument
for the cost-effectiveness of this therapy.
6 | GLUCOSE-RESPONSIVE INSULIN
DELIVERY
The challenge of tailoring insulin therapy to manage glucose excur-
sions in T2D can be overcome with the use of glucose-responsive
insulin delivery, commonly referred to as “closed-loop” or “artificial
pancreas” systems. Real-time glucose measurements from a CGM
device are communicated to a control algorithm which computes and
directs insulin delivery via an insulin pump.
Earlier features of glucose-responsive insulin delivery systems
include the low-glucose-suspend feature, which interrupts insulin
delivery below a defined glucose threshold, and predictive low-glu-
cose-suspend which predicts pending hypoglycaemia and suspends
insulin delivery in advance.97 No studies have been performed to
assess the efficacy of these features in reducing the frequency and
severity of hypoglycaemia in T2D; studies are limited to the T1D
population.98,99
With the recognition that postprandial glycaemic excursions are
particularly challenging, the next phase of development was a
“hybrid” closed-loop system, which requires meal announcements and
initiation of a pump-delivered meal bolus by the user. The basal rate is
automated for the remainder of the time between meals. Studies of
inpatient and outpatient use of this system in people with T1D led to
the introduction of the first hybrid closed-loop system in the United
States in 2017 for use in T1D (670G pump; Medtronic Diabetes, Nor-
thridge, California).100 Since then a number of other hybrid closed-
loop systems have been developed.6
The ultimate goal in reducing the burden of diabetes manage-
ment is the fully automated closed-loop system which eliminates
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the need to undertake manual mealtime boluses. A number of RCTs
have been carried out to assess the use of the fully closed-loop sys-
tem for inpatients with T2D, and these have consistently shown
increased time in target glucose range and no increased risk of
hypoglycaemia, suggesting a safe and effective method of glucose
control in this population.101–105 Furthermore, the inclusion of
inpatients on haemodialysis or artificial nutrition suggests that
closed-loop insulin delivery is adaptable and effective in patients
with comorbidities complicating diabetes management.102,105 The
largest RCT by Bally et al,101 including 136 inpatients with T2D,
showed time in range of 65.8% with closed-loop therapy, compared
to 41.5% in the control group. User satisfaction was high, with 89%
of users reporting that they were happy to have their glucose levels
controlled by the system.101
To date, no studies have been published on the use of the fully
closed-loop system in T2D in the outpatient setting, however there
are three studies ongoing to clarify if this is a safe, viable and cost-
effective option for this population outside the hospital environment
(NCT04025775, NCT04701424, NCT04233229).
7 | FUTURE DIRECTIONS
The majority of research into diabetes technology has been carried
out in developed countries, however, it should be noted that the
majority of people with T2D live in low- and middle-income coun-
tries.1 Many of these devices are unattainable by these groups due
to cost, poor health literacy and educational deprivation. Indeed, in
developed countries many people with T1D and T2D currently self
fund diabetes technologies that are not routinely available from
their healthcare provider.106 A key challenge is ensuring equity of
access to diabetes technologies across all nations and socioeco-
nomic groups. There is a requirement for less complex technologies
with provisions for cognitive and sensory impairment in order to
expand the user base for these technologies and improve quality of
life for those with limited technical ability or older people with
T2D. Further clinical trials including this subgroup of people with
T2D are required.
Studies to date have consistently shown positive outcomes
with insulin pump use in people with T2D suboptimally controlled
on MDI, however, professional guidelines do not currently support
routine use in this group. The integration of insulin pumps with
other diabetes technologies developed in the past decade has
opened the gateway to methods of optimally controlling blood glu-
cose and minimizing user burden, including closed-loop insulin
delivery. Limited access to insulin pumps hinders widespread adop-
tion of these technologies into routine care. Further evidence from
RCTs and health economics assessments are required to support
their adoption on a larger scale.
Closed-loop systems that enable glucose-responsive insulin deliv-
ery are now commercially available for people with T1D. Further
research is warranted to assess the efficacy and safety of this treat-
ment in T2D.
8 | CONCLUSIONS
Glucose control for people with T2D remains challenging, particularly
in those with a severe insulin deficit necessitating exogenous insulin
delivery. There is a clinical need for safer and more user-friendly
methods of insulin delivery. Advances in diabetes technologies over
the past decade have provided cost-effective and valuable tools to
safely commence insulin therapy and manage the disease effectively.
Studies in inpatients with T2D have shown promising results for fully
closed-loop insulin therapy. Further research is required to determine
if this can be extended to the outpatient population with T2D.
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